SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Valuation After FDA Clearance For Phase II Immunotherapy Trial
FDA clearance puts CS2009 in focus for CStone investors
CStone Pharmaceuticals (SEHK:2616) said the U.S. FDA has cleared its IND for a Phase II trial of immunotherapy candidate CS2009 in advanced solid tumors, expanding an ongoing global multicenter study.
See our latest analysis for CStone Pharmaceuticals.
The FDA clearance comes as CStone’s share price sits at HK$5.91, with a 7 day share price return of 14.98% and a 1 year total shareholder return of 113.36%. This suggests momentum has...